Roivant Sciences Ltd.

ROIV

NASDAQ

Healthcare

Biotechnology

London, GB908 employeesroivant.com

$28.30

+0.46(1.65%)

Mkt Cap $20.3B

$9.08

$29.72

52-Week Range

At a Glance

AI-generated

8-K

Roivant announced preliminary cash of $4.3 billion, a $109.7 million share repurchase, a new Phase 2b/3 trial for brepocitinib in LPP, and reported that Immunovant's Phase 3 batoclimab studies in TED failed to meet their primary endpoint.

$20.3B

Market Cap

$14M

Revenue

-$831M

Net Income

Employees908

Fundamentals

How The Business Makes Money

Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.

Industry Biotechnology

Activity

What Changed Recently

Financial Results

Apr 1, 2026

shall not be deemed incorporated by reference into any other filing with the SEC made by the Company, whether made before or after the date hereof, regardless o

Material Agreement

Mar 22, 2026

. Entry into a Material Definitive Agreement The disclosure set forth in Item 1.01 of the Original 8-K is hereby incorporated by reference. As described in the

Material Agreement

Mar 2, 2026

. Entry into a Material Definitive Agreement On March 3, 2026 (the “Effective Date”), Genevant Sciences GmbH (“Genevant”), a subsidiary of Roivant Sciences Ltd.

Financial Results

Feb 5, 2026

. Results of Operations and Financial Condition” (including Exhibit 99.1) shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exc

Regulation FD

Mar 2, 2026

, including Exhibit 99.1, shall not be deemed incorporated by reference into any other filing with the U.S. Securities and Exchange Commission made by the Compa

Company Profile

CIK0001635088

ISINBMG762791017

CUSIPG76279101

Phone44 2074 003 347

Address11-12 St. James's Square, London, SW1Y 4LB, GB

SEC EDGAR